Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

被引：0
|
作者：
Wiken, T. [1 ,2 ]
Hoivik, M. L. [1 ,2 ]
Buer, L. [1 ]
Bolstad, N. [3 ]
Moum, B. A. [1 ,2 ]
Medhus, A. W. [1 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P376
引用
收藏
页码：I378 / I379
页数：2
相关论文
共 50 条
  • [31] Switching from intravenous to subcutaneous VEDOlizumab formulation in ulcerative colitis patients in clinical remission: the SVEDO Study, a multicenter IG-IBD study
    Ribaldone, D. G.
    Parisio, L.
    Variola, A.
    Bossa, F.
    Castiglione, F.
    Marzo, M.
    Piazza, N.
    Aratari, A.
    Savarino, E. V.
    Bodini, G.
    Mastronardi, M.
    Micheli, F.
    Mazzuoli, S.
    Ascolani, M.
    Vigano, C.
    Cappello, M.
    Bezzio, C.
    Ciccocioppo, R.
    Scardino, G.
    Sarli, E.
    Pugliese, D.
    Scaldaferri, F.
    Napolitano, D.
    Todeschini, A.
    Geccherle, A.
    Colaci, N.
    Guerra, M.
    Annese, M.
    Testa, A.
    Caiazzo, A.
    Conforti, F. S.
    Festa, S.
    Lorenzon, G.
    Marra, A.
    Magiotta, A.
    Baccini, F.
    Amato, A.
    Vernero, M.
    Caprioli, F.
    Caviglia, G. P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1176 - I1176
  • [32] P0744 Observational Real-World Study of Switching from Intravenous to Subcutaneous Vedolizumab in IBD Patients: Clinical and Pharmacokinetic Analysis
    Palomares, M. T. Diz Lois
    de-Acosta, M. Barreiro
    Lopez, A. Baz
    Sanchez, A. Porta
    Pazos, L. Elberdin
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1441 - i1442
  • [33] Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
    Elisabetta Fenu
    Vasily Lukyanov
    Annabel Acs
    Xenia Radu
    Stephanie Stypa
    Aren Fischer
    John K. Marshall
    Mark Oppe
    PharmacoEconomics - Open, 2022, 6 : 519 - 537
  • [34] Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
    Bacsur, Peter
    Resal, Tamas
    Sarlos, Patricia
    Ilias, Akos
    Sumegi, Liza Dalma
    Kata, Diana
    David, Anett
    Farkas, Bernadett
    Ivany, Emese
    Balint, Anita
    Bosze, Zsofia
    Fabian, Anna
    Bor, Renata
    Szepes, Zoltan
    Afif, Waqqas
    Bessissow, Talat
    Farkas, Klaudia
    Lakatos, Peter L.
    Molnar, Tamas
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [35] Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab
    Canete, Fiorella
    Gonzalez-Gonzalez, Laura
    Domenech, Eugeni
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (04): : 377 - 378
  • [36] Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
    Rajab, Fatima
    Mujahid, Aleena
    Rajab, Hadia
    Alvi, Abdullah
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (04) : 716 - 717
  • [37] Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
    Lim, Samuel Hsiang
    Gros, Beatriz
    Sharma, Esha
    Lehmann, Anouk
    Lindsay, James O.
    Caulfield, Louise
    Gaya, Daniel R.
    Taylor, Jo
    Limdi, Jimmy
    Kwok, Jon
    Shuttleworth, Elinor
    Dhar, Anjan
    Burdge, Gemma
    Selinger, Christian
    Cococcia, Sara
    Murray, Charles
    Balendran, Karthiha
    Raine, Tim
    George, Becky
    Walker, Gareth
    Aldridge, Robin
    Irving, Peter
    Lees, Charlie W.
    Samaan, Mark
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (08) : 1284 - 1294
  • [38] Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with Inflammatory Bowel Disease. One year follow-up
    Andres Pascual, L.
    Arias Garcia, L.
    Saiz Chumillas, R. M.
    Chivato Martin-Falquina, I.
    Sicilia Aladren, B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1083 - I1084
  • [39] Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
    Todeschini, A.
    Geccherle, A.
    Signoretto, P.
    Fasoli, E.
    Variola, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 551 - 552
  • [40] Safety study on switching from intravenous to fixed-dose subcutaneous formulation of pertuzumab and trastuzumab
    Abe, Tomoya
    Sagara, Atsunobu
    Suzuki, Takayuki
    Okada, Daichi
    Takei, Daisuke
    Matsuzaka, Kazumasa
    Kobayashi, Honoka
    Hiraide, Makoto
    Sano, Motohiko
    Nakayama, Toshiaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (03)
12345